Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
GAITHERSBURG, MD -- October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T …
Affimed Doses First Patient in Phase 1 Clinical Trial of Natural Killer Cells in Combination with AFM13
Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their i…
Verastem Oncology Announces Closing of Duvelisib Sale to Secura Bio
BOSTON - Sep. 30, 2020 - Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medici…
Patient Education Webcasts
Insight into Chronic Myeloid Leukemia (CML)
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed AML
GAITHERSBURG, MD - September 23, 2020 – NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunoth…
Magrolimab Receives FDA Breakthrough Therapy Designation for Treatment of MDS
FOSTER CITY, Calif., September 15, 2020 - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has gr…
Media resources
Email
Contact us for inquiries and interview requests.
Press Kit
Explore details for journalists and media outlets.
Brand Center
Access approved logos, guidelines, and other assets.